Tobacco Cessation |

The Value of FeNO and Lipid Profile in Predicting the Cardiovascular Risk in Symptomatic Smokers FREE TO VIEW

Ligia Puiu, MD; Anca Petrovan, MD; Oana-Claudia Deleanu, MD; Florin Mihaltan, MD; Oana Arghir, PhD
Author and Funding Information

Hospital of Pneumophthisiology, Baia-Mare, Maramures County, Romania; University Hospital of Infectious Diseases, Cluj-Napoca, Romania; National Institute of Pneumology “Marius Nasta”, Bucharest, Romania; Ovidius University Medicine Faculty, Constanta, Romania

Chest. 2015;148(4_MeetingAbstracts):1068A. doi:10.1378/chest.2270484
Text Size: A A A
Published online


SESSION TITLE: Tobacco Cessation and Prevention

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Monday, October 26, 2015 at 07:30 AM - 08:30 AM

PURPOSE: To assess the value of fractional Nitric Oxide (NO) concentration in Exhaled Breath (FeNO) in predicting the risk of cardiovascular disease among respiratory symptomatic adult subjects in an Out-patient Pulmonology Health Unit.

METHODS: 85 respiratory symptomatic outpatients, mean aged 52.9±9.7 year-old, were grouped in smokers (n=43) and nonsmokers (n=42). Demographic, anthropometric and spirometric parameters were determined, as well as FeNO, measured by using the hand-held Niox-Mino, according to international guidelines. Considering the altered bioactivity of NO may be convert to pro-oxidant species, such as peroxynitrite and nitrogen dioxide, initiating the process of lipid peroxidation, forming nitrated lipids or proteins, other determinations included glycemia, plasma routine lipid profile (total cholesterol-TC, low density lipoprotein cholesterol-LDLc, high density lipoprotein cholesterol-HDLc, triglycerides-TG), usefull in evaluating Castelli risk Index I and II (TC/HDLc and LDLc/HDLc respectively), Atherogenic Coefficient (AC) {(Non-HDLc)/HDLc}, and Atherogenic Index of Plasma (AIP) {(logTG)/HDLc} were performed. Spearman correlations tests and one-way ANOVA test were calculated.

RESULTS: FeNO was significantly lower in smokers versus nonsmokers (p=0.0002), while AC increased in smokers (p=0.05). In all subjects (smokers and nonsmokers) Spearman's correlation revealed significant interactions between FeNO and Castelli Risk Index I (r=-0.32;p=0.002); Castelli Risk Index II (r=-0.34;p=0.001); glycemia (r=-0.25;p=0.02); respectively AC (r=-0.22;p=0.03).

CONCLUSIONS: Smokers have a greater atherogenic coefficient. In symptomatic patients, FeNO interacts with lipid oxidation pathways, decreasing in smokers.

CLINICAL IMPLICATIONS: A better understanding of FeNO, as a marker of airway inflammation, and its relations with lipid profile and atherogenic indexes can better predict the risk of heart disease in smokers.Tobacco cessation may prevent the occurence of cardiovascular diseases.

DISCLOSURE: The following authors have nothing to disclose: Ligia Puiu, Anca Petrovan, Oana-Claudia Deleanu, Florin Mihaltan, Oana Arghir

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543